Analysts’ Viewpoint
Increase in geriatric population and rise in prevalence of primary progressive multiple sclerosis (PPMS) across the globe are key factors that are positively impacting market statistics. Governments of developed and developing countries are taking initiatives to raise public awareness about the various available treatment options for multiple sclerosis. This is resulting in market expansion.
Improvements in healthcare infrastructure carried out by government and non-governmental organizations are expected to propel market growth in the near future. Key players are investing significantly in R&D activities to grab lucrative primary progressive multiple sclerosis treatment market opportunities.
Primary progressive multiple sclerosis is a neurodegenerative disease, wherein a person’s immunity system adversely affects the outer protective covering of nerve cells in the brain called myelin. The nerves in and around the brain and spinal cord get damaged due to the disease. Vision-related nerves may also be affected.
PPMS is usually observed in people aged between 35 years and 40 years. Early symptoms of the disease are often subtle. These include difficulty in walking that develops over time. Initially, the affected individual experiences very little or no relapse of the disease. The disability increases gradually. Symptoms may appear to remain stable for protracted periods of time.
Request a sample to get extensive insights into the Primary Progressive Multiple Sclerosis Treatment Market
Growth in prevalence of primary progressive multiple sclerosis is significantly impacting market development. Women are more susceptible to multiple sclerosis than men. Rise in number of people with multiple sclerosis is expected to boost the demand for drugs and medical attention related to the disease during the forecast period. Furthermore, the effectiveness of drugs and quick advances in MS therapy are anticipated to fuel the market in the near future.
According to a study carried out by the National Multiple Sclerosis Society (NMSS) in September 2020, there were 2.8 million people living with multiple sclerosis (MS) globally. This suggests that someone somewhere in the world is diagnosed with multiple sclerosis every five minutes. Thus, around 0.5 million people in the world are estimated to be living with PMSS. Hence, rise in prevalence of PPMS is projected to augment the global market share during the forecast period.
Rise in healthcare expenditure, which aids in the improvement of related infrastructure, is a crucial factor influencing market expansion. According to the primary progressive multiple sclerosis treatment market forecast report, growth in awareness about multiple sclerosis due to initiatives by various public and private organizations is likely to fuel the industry during the forecast period. Increase in geriatric population and constantly evolving lifestyles of the people are also likely to accelerate market growth.
Request a custom report on Primary Progressive Multiple Sclerosis Treatment Market
Primary progressive multiple sclerosis treatment market growth can be ascribed to the increase in emphasis on research and development activities to develop innovative drugs by major players. Currently, Roche's OCREVUS (Ocrelizumab) is available in the market. However, its efficacy is limited. Currently, 19 products are under clinical development; of these, three are in phase 3 of clinical trials.
Players in the market are increasing their R&D activities for the treatment of the PPMS disease. Several governments and private organizations are funding a number of schemes and programs to provide support to improve the quality of life of individuals affected by the disease.
As per the market segmentation, the industry has been divided into approved drugs and pipeline drugs based on drug type. Currently, Roche’s Ocrelizumab with the brand name OCREVUS is the only drug available in the market for the treatment of PPMS. Hence, the approved drugs segment is anticipated to dominate during the forecast period.
Pipeline drugs are expected to obtain approval over the next few years. More than 15 drugs are under clinical trials in phases two and three. Thus, the pipeline drugs segment is anticipated to grow at the highest CAGR during the forecast period, owing to the increase in investment in R&D by companies across the globe.
Based on distribution channel, the business has been segmented into retail pharmacies, e-commerce, and others. The retail pharmacies segment is projected to dominate during the forecast period, primarily due to the availability of favorable health reimbursement policies. Increase in number of retail pharmacies supported by government and private organizations is contributing to market progress.
The e-commerce segment is likely to grow at the highest CAGR during the forecast period, owing to the rise in number of online portals distributing prescription drugs across the world. Primary progressive multiple sclerosis treatment industry demand is increasing, with growth in online home delivery of pharmaceuticals.
North America’s market size is anticipated to increase during the forecast period. Rise in prevalence of PPMS in the U.S. and increase in demand for therapeutic drugs for the treatment of PPMS are the key factors fueling market development in the region.
Asia Pacific is projected to register the highest CAGR during the forecast period, owing to the rise in awareness about the treatment for primary progressive multiple sclerosis among the population. Improvement in healthcare infrastructure in economies such as India and China is also contributing to market expansion in the region.
The global market is fragmented, with the presence of a large number of prominent players controlling majority of the share. Some of the major companies in PPMS treatment market across the globe are F. Hoffmann-La Roche Ltd., Sanofi, Mapi Pharma Ltd., Atara Biotherapeutics, Takeda Pharmaceuticals International, Inc., AB Science, and Mallinckrodt. These players are engaged in research and development activities and have drugs in the pipeline for clinical trials.
The market report profiles key players in terms of product portfolio, recent developments, company overview, financial overview, business strategies, and business segments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 828.4 Mn |
|
Market Forecast Value in 2031 |
More than US$ 3.2 Bn |
|
Growth Rate (CAGR) 2022-2031 |
14.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, pipeline analysis and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 828.4 Mn in 2021
It is projected to reach more than US$ 3.2 Bn by 2031
The CAGR is anticipated to be 14.7% during the forecast period
The CAGR stood at 57.8% from 2017 to 2021
North America is expected to hold major share during the forecast period
F. Hoffmann-La Roche Ltd., Sanofi, Mapi Pharma Ltd., Atara Biotherapeutics, Takeda Pharmaceuticals International, Inc., AB Science, and Mallinckrodt
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Product/Brand Analysis
5.5. Major Research Institutes Involved
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2017 - 2031
6.3.1. Approved Drugs
6.3.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Type
7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Distribution Channel, 2017 - 2031
7.3.1. Retail Pharmacies
7.3.2. E-commerce
7.3.3. Others
7.4. Market Attractiveness By Distribution Channel
8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region
9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Type, 2017 - 2031
9.2.1. Approved Drugs
9.2.2. Pipeline Drugs
9.3. Market Value Forecast By Distribution Channel, 2017 - 2031
9.3.1. Retail Pharmacies
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast By Country, 2017 - 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2017 - 2031
10.2.1. Approved Drugs
10.2.2. Pipeline Drugs
10.3. Market Value Forecast By Distribution Channel, 2017 - 2031
10.3.1. Retail Pharmacies
10.3.2. E-commerce
10.3.3. Others
10.4. Market Value Forecast By Country, 2017 - 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2017 - 2031
11.2.1. Approved Drugs
11.2.2. Pipeline Drugs
11.3. Market Value Forecast By Distribution Channel, 2017 - 2031
11.3.1. Retail Pharmacies
11.3.2. E-commerce
11.3.3. Others
11.4. Market Value Forecast By Country, 2017 - 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country
12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2017 - 2031
12.2.1. Approved Drugs
12.2.2. Pipeline Drugs
12.3. Market Value Forecast By Distribution Channel, 2017 - 2031
12.3.1. Retail Pharmacies
12.3.2. E-commerce
12.3.3. Others
12.4. Market Value Forecast By Country, 2017 - 2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country
13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2017 - 2031
13.2.1. Approved Drugs
13.2.2. Pipeline Drugs
13.3. Market Value Forecast By Distribution Channel, 2017 - 2031
13.3.1. Retail Pharmacies
13.3.2. E-commerce
13.3.3. Others
13.4. Market Value Forecast By Country, 2017 - 2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Sanofi
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Mapi Pharma Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Atara Biotherapeutics
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Takeda Pharmaceuticals International, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. AB Science
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Mallinckrodt
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
List of Tables
Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 03: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 04: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 05: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 06: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Region, 2021 and 2031
Figure 07: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 08: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 10: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 11: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 12: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 13: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country, 2021 and 2031
Figure 14: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 15: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 17: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 18: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 19: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 20: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 21: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 22: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 24: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 25: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 26: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 28: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 29: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 31: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 32: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 33: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 34: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 35: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
Figure 38: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 39: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 40: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 41: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 42: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 43: Global Primary Progressive Multiple Sclerosis Treatment Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Primary Progressive Multiple Sclerosis Treatment Market
